Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vigil Neuroscience, Inc. - Common Stock (NQ: VIGL )

3.950 +0.230 (+6.18%)
Streaming Delayed Price Updated: 10:58 AM EDT, Jun 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,783
Open 3.700
Bid (Size) 3.850 (2)
Ask (Size) 3.950 (1)
Prev. Close 3.720
Today's Range 3.591 - 3.950
52wk Range 2.470 - 10.22
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
3 Penny Stocks With the Power to 10X Your $1k Investment: June Edition
Penny stocks are risky because of their insane volatility — but these have a chance to 10x your investments. 
Via InvestorPlace

Performance

YTD
+13.83%
+13.83%
1 Month
+19.34%
+19.34%
3 Month
+41.58%
+41.58%
6 Month
+8.22%
+8.22%
1 Year
-54.96%
-54.96%

More News

Read More
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
Via InvestorPlace
Vigil Neuroscience to Present in Upcoming June Investor Conferences
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience: Q4 Earnings Insights
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
VIGL Stock Earnings: Vigil Neuroscience Beats EPS for Q1 2024
Via InvestorPlace
Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
From Vigil Neuroscience, Inc.
Via GlobeNewswire
VIGL Stock Earnings: Vigil Neuroscience Misses EPS for Q4 2023
Via InvestorPlace
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Why Is Rare Neurological Disease Focused Vigil Neuroscience Stock Trading Lower Today?
Via Benzinga
Why Dolby Laboratories Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
US Stocks Edge Lower; Housing Starts Rise In October
Via Benzinga
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.